玻璃体切除联合曲安奈德玻璃体腔注射治疗孔源性视网膜脱离

目的 探讨玻璃体切除联合曲安奈德(TA)玻璃体腔内注射治疗合并脉络膜脱离的孔源性视网膜脱离的临床疗效和安全性.方法 观察采用玻璃体切除联合曲安奈德玻璃体腔内注射治疗合并脉络膜脱离的孔源性视网膜脱离15例患者(15眼),术后不再全身应用糖皮质激素,仅给予激素眼液点眼.结果 术后随访时间6～30个月,平均(19±9.5)个月.一次手术视网膜复位率100%.术后3个月硅油取出后,2例视网膜脱离复发,1例再次剥膜充填硅油后视网膜复位;另1例放弃治疗.视网膜总复位率为93.3%(14/15).术后并发症包括:4例术后眼压升高,均局部用药控制,5例出现晶状体后囊下皮质局限性混浊.结论 玻璃体切除联合(TA)玻璃体腔内注射治疗合并脉络膜脱离的孔源性视网膜脱离,可以明显减轻术后葡萄膜炎症反应,从而减少PVR的发生,显著提高手术的成功率.

Pars plana vitrectomy combined with intravitreal triamcinolone acetonide for the treatment of rhegmatogenous retinal detachment complicated with choroidal detachment

Objective To investigate the treatment role of vitrectomy combined with intravitreal triamcinolone acetonide (TA) for rhegmatogenous retinal detachment (RRD) complicated with choroidal detachment (CHD).Methods Fifteen cases (15 eyes) of RRD complicated with CHD underwent vitrectomy combined with intravitreal TA.Results At mean follow-up of 19±9.5 months, the total final anatomic success rate was 14/15 (93.3%).Conclusions The results suggest that vitrectomy combined with intravitreal TA is a safe and effective technique for the treatment of RRD complicated with CHD.